GSK plc and 35Pharma Inc.: what the $950m HS235 deal changes in pulmonary hypertension therapy
GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.
Pharma & Biotech
Pharma & Biotech
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.
Pharma & Biotech
Eton Pharmaceuticals expands rare endocrine portfolio with FDA-backed liquid desmopressin
FDA approves DESMODA oral solution for central diabetes insipidus. Explore what this means for dosing precision and rare endocrine care.
Pharma & Biotech
What Longeveron Inc.’s Phase 2b results mean for regenerative medicine in aging populations
Longeveron Inc. publishes Phase 2b laromestrocel data in frailty. Explore what it means for stem cell therapy and regulatory next steps.
Medical Devices & Diagnostics
20/20 BioLabs and IBM collaboration signals new direction in preventive diagnostics
20/20 BioLabs launches AI-powered OneTest for longevity risk modeling. Discover what this means for preventive diagnostics and regulation.
Pharma & Biotech
Vir Biotechnology’s VIR-5500 tests whether dual-masked T-cell engagers can finally work in metastatic prostate cancer
Vir Biotechnology’s VIR-5500 shows early promise in metastatic prostate cancer. Find out what changes, what remains uncertain, and what comes next.
Pharma & Biotech
What Arcus Biosciences’ casdatifan data reveal about durability limits in late-line renal cell carcinoma
Arcus Biosciences’ casdatifan data challenge assumptions about HIF-2α inhibition in kidney cancer. Explore what changes next and what risks remain.
Pharma & Biotech
Why Gilead Sciences’ Arcellx acquisition reshapes the competitive dynamics of BCMA CAR T therapy
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.
Pharma & Biotech
Why Daiichi Sankyo is betting early on SylamoreBio’s SyLEC delivery platform for CNS programs
SylamoreBio partners with Daiichi Sankyo to test SyLEC CNS delivery technology. Find out what this collaboration changes for brain drug development.
Pharma & Biotech
How subcutaneous amivantamab approval in Europe could reshape EGFR-mutated NSCLC treatment workflows
EU approves subcutaneous amivantamab for expanded EGFR lung cancer dosing. Discover what this changes for clinicians and health systems.